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A Ab bs st tr ra ac ct t
Paragangliomas are rare tumours of the autonomic nervous system and occur in sporadic and hereditary forms.
They are usually benign and have a low mortality. However, they cause significant morbidity related to their
mass effect. Genetic predisposition can occur within the familial tumour syndromes multiple endocrine neoplasia
type 2 (MEN 2), von Hippel-Lindau (VHL) and neurofibromatosis type 1 (NF-1), or be due to mutations in genes
specific to the development of paraganglioma only. Compared to sporadic forms, familial paragangliomas
tend to present at a younger age and at multiple sites. Tumours should be diagnosed and resected as early as
possible, as it has been shown that morbidity is related to tumour size. This article gives an overview of the
current literature on the origin of the different forms of paragangliomas, DNA diagnosis, as well as biochemical
and radiological screening guidelines.
I In nt tr ro od du uc ct ti io on n
Paraganglia are groups of neuroendocrine cells
scattered throughout the body. They are related to the
autonomic nervous system. Mostly they occur in the
head (glomus tympanicum and jugular), neck (glomus
caroticum and vagal), adrenal medulla, and in the
extra-adrenal region in the sympathetic ganglia. During
embryogenesis, cells from the neural crest migrate to
the sympathetic and parasympathetic nervous system
and adrenal medulla. Tumours that develop in cells
from paraganglia are called paragangliomas and are
classified according to their origin and location (Fig. 1). 
Genetic predisposition for paragangliomas exists in
relation to the well-known tumour syndromes multiple
endocrine neoplasia type 2 (MEN 2), von Hippel-Lindau
(VHL) and neurofibromatosis type 1 (NF-1). Besides these
syndromes, paragangliomas occur in familial forms
without other types of tumours. Compared with sporadic,
solitary paragangliomas, familial tumours occur at 
a younger age and often are multiple in origin. 
Paragangliomas that develop in the parasympathetic
ganglia mostly have no hormonal activity, whereas
paragangliomas derived from sympathetic ganglia can
produce catecholamines. Only paragangliomas in the
adrenal medulla can produce both noradrenalin andH He er re ed diit ta ar ry y C Ca an nc ce er r iin n C Clliin niic ca all P Pr ra ac ct tiic ce e 2006; 4(4) 170
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adrenalin and are called phaeochromocytomas. Extra-
-adrenal paragangliomas may produce noradrenalin
and then stain dark-brown with chromic acid just like
phaeochromocytomas (from Greek phaeo).
In a part of the peripheral autonomic nervous system
the concentration of oxygen and carbon dioxide in the
blood as well as the pressure in the vascular system are
measured. This information is passed on to centres in
the brain stem, where the frequency of heart rhythm and
respiration is regulated. By means of neural stimuli and
hormones (such as catecholamines) the blood stream in
the arterioles is regulated. Besides this central regulation
by the autonomic nervous system and hormones, most
tissues are able to contract or relax the muscles in their
vessel walls in a process of autoregulation. Peripheral
chemoreceptors in the glomus caroticum and glomus
aorticum are stimulated if oxygen pressure decreases
and carbon dioxide pressure increases. The consequence
is peripheral vasoconstriction. Baroreceptors in cells of
the aorta and neck arteries regulate blood pressure by
stretching of these cells and vasodilatation.
Paragangliomas have their origin especially in
neuroendocrine cells that have chemoreceptors. These
cells are localized near the great vessels and mostly they
develop in the head and neck region. Common
characteristics are: they grow slowly and they are benign.
The prevalence of paragangliomas is approximately 1 to
30,000. About 10 to 50% of all paragangliomas are
familial. Many subjects with genetic predisposition do not
have phenotypic expression of the disease. This pheno-
menon is explained by a mechanism of ‘imprinting’ (see
below). The hereditary predisposition occurs in an equal
male-to-female ratio (autosomal dominant inheritance).
Expression may occur as early as at age five, whereas in
25% of all carriers expression is found before the age of
25 years. Often, in about 50% of disease gene carriers,
there is multicentric involvement. In fact, multicentricity is
an indication for hereditary disease in patients with
apparently sporadic disease. Sometimes, in about 10%
of familial cases of paragangliomas, they occur in the
adrenal medulla and produce noradrenalin and
adrenalin (phaeochromocytomas). Most frequently,
tumours in the glomus caroticum occur (60%) followed
by paragangliomas of the inner ear (jugulotympanic
paragangliomas). Less than 10% of paragangliomas are
malignant.
S Sy ym mp pt to om ma at to ol lo og gy y 
In most patients a local tumour in the neck
develops, initially at one side. Mostly the swelling is
painless, but it increases slowly in diameter and is
usually located under the edge of the jaw. Interruption
of nervous tissue may occur by pressure at the base of
the skull, e.g. passage of the glossopharyngeal nerve,
vagal nerve, and/or accessory in the jugular foramen.
Complaints such as choking, defect in speech, tickling
cough and pain and weakness in shoulder muscles
may occur. Hoarseness and Horner’s syndrome
frequently occur. In jugulotympanic paragangliomas,
tinnitus with the frequency of heart beating, dizziness
and blurred vision may occur. Later on, deafness, facial
nerve palsy and pain in the inner ear develop. 
Sometimes paragangliomas produce amines such
as serotonin and/or noradrenalin or their precursors.
Production of noradrenalin may evoke hypertension,
headache, palpitations and perspiration. These
complaints occur in 30% of patients. Paragangliomas
in the adrenal glands may produce adrenalin and this
occurs in 5% of patients. Infrequently, proteins such as
vasoactive intestinal peptide (VIP) or adrenocorticotropic
hormone are produced. Depending on the hormone
produced, specific complaints may develop. This occurs
only in 2 to 3 % of patients with paragangliomas.
F Fi ig g. . 1 1. . Paragangliomas classified according to their origin and location
Paragangliomas have their origin in cells derived from the
embryological neuroectoderm. There are 4 types of paragangliomas
(according to Kleinsasser O. Arch. Klin. Exp. Ohren, Nasen,
Kehlkopfheilkunde, 1064; 184: 214-25 and Glenner GG, Grimley PM,
Atlas of tumor Pathology 1974; p. 18) 
1. Branchiomeric group: In the region of the embryological branchiomeres
(jugulotympanic ganglion, carotid body, laryngeal ganglia, subclavian
ganglion, aorticopulmonary ganglion). There is a close relationship with
blood vessels.
2. Intravagal group: In the region of the parasympathetic nerves (jugular
ganglion, nodose ganglion). They have their origin within the perineurium.
3. Aortosympathetic group: In the region of the sympathetic nerves of the
aorta. 
4. Visceral autonomic group: in the nervous system of the heart, digestive
tract, liver hilus, and bladder. 
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D Di ia ag gn no os si is s
Frequently assessment of the diagnosis of
paraganglioma by ultrasound is difficult, especially
when the primary tumour is located at the base of the
skull. The classical applied method of angiography is
replaced by magnetic resonance angiography (MRA).
In most cases, patients are referred to the out-patient
department of throat, nose, and ear diseases because
of their complaints of nerve palsy and/or swelling in
the neck. This specialist together with the head and
neck surgeon will form the team for treatment.
N Na at tu ur ra al l h hi is st to or ry y
The morbidity of the disease may seriously affect
quality of life. In this way swallowing and speech defects
and even hemiplegia are caused by damage of the
peripheral or central nervous system (cerebrovascular
accident, CVA). The final life expectancy is shortened.
P Pa at th ho ol lo og gy y
Paragangliomas are strongly vascularized. From 
a histological view, they have a thin capsule and are
composed of round polygonal chief cells arranged in
compact cell nests (‘Zellballen’) or trabecular formations.
Spindle-like or supporting (sustentacular) cells are situated
peripherally. In benign paragangliomas pleomorphism
of the nucleus, necrosis, mitosis and some local invasion
may be observed. Metastases in lymph nodes, lungs or
bones are criteria of malignancy. This occurs in less than
10%. The neuroendocrine character can be demonstrated
by immunohistochemical methods. Neuron-specific
enolase (NSE), synaptophysin and chromogranin may be
demonstrated in chief cells. 
By means of electron microscopy ultrastructural
neurosecretory granules are demonstrable. They may
contain biogenic amines such as noradrenalin, adrenalin,
serotonin or their precursors (dopamine and 5-hydro-
xytryptophane, respectively). Unfortunately, at this moment
it is impossible to predict the prognosis on the basis of
histological grounds. Criteria such as mitoses, nuclear
pleomorphism or invasiveness appear to be unreliable.
In the near future, molecular biochemical examination
(expression profiles) may provide more insight into
additional mutations and ‘multistep carcinogenesis’.
M Mo ol le ec cu ul la ar r g ge en ne et ti ic cs s
H He er re ed di it ta ar ry y p pr re ed di is sp po os si it ti io on n 
If bilateral paraganglioma are assessed, in most
cases a hereditary disease is present. The predisposition
is passed from one of the parents to her/his child or 
a de novo mutation in the germ line of the patient
her/himself has occurred. 
The genetic defect of paragangliomas is an
inactivating mutation in one of the paraganglioma
genes, the so-called P PG GL L g ge en ne es s. These mutations may
occur somatically or be present in the germ line.
Somatic, inactivating mutations result in sporadic,
mostly solitary tumours. If a germ line mutation is
present, a hereditary form will occur, mostly multiple
and at a young age. 
G Ge en ne es s r re es sp po on ns si ib bl le e f fo or r t th he e d de ev ve el lo op pm me en nt t
o of f p pa ar ra ag ga an ng gl li io om ma a
M Mo ol le ec cu ul la ar r b bi io ol lo og gy y o of f r re es sp pi ir ra at ti io on n
In primates adenosine triphosphate (ATP) is the
source of energy for most biological processes. Energy
necessary for synthesis of ATP is obtained by oxidation
of nutrients. Two processes are involved in transformation
of energy: citric acid or tricarboxylic acid (TCA) cycle and
oxidative phosphorylation (respiration chain). Both
processes occur in the mitochondria (Fig. 2). 
In the process of oxidative phosphorylation 5 enzyme
complexes (I-V) are involved, which are anchored in the
inner membrane. Three genes encoding the proteins B,
C and D of complex II are involved in the development
of paragangliomas. All four different proteins (A, B, C
and D) of complex II are encoded by the nuclear
genome. The proteins C and D are anchored in the
inner mitochondrial membrane. The proteins A and B
have a catalytic function (enzymes). 
O Or ri ig gi in n o of f p pa ar ra ag ga an ng gl li io om ma as s
Mutations in DNA of genes encoding enzymes called
succinate dehydrogenase (SDH) are associated with
development of paragangliomas. The derived proteins
SDH-B, -C and -D are enzymes that belong to complex
II of the respiratory chain of mitochondria (Fig. 2) [1].
Chemoreceptors detect a shortage of oxygen.
Hypoxia can be compensated by the lungs by
breathing faster and deeper. In the cells of the
paraganglia, hypoxia will promote expression of
factors that stimulate angiogenesis. It is generally
assumed that “vasoactive endothelial growth factor”
(VEGF) and “reactive oxygen species” (ROS) are
responsible directly for cell division and tumour
development. Thus paragangliomas will occur more
frequently in smokers and people living at a high
altitude (in Tibet, in the Andes mountains) and in
patients with chronic pulmonary diseases [2].H He er re ed diit ta ar ry y C Ca an nc ce er r iin n C Clliin niic ca all P Pr ra ac ct tiic ce e 2006; 4(4) 172
If in a cell of a paraganglioma a mutation is present
in one of the SDH genes, insufficient ATP will be available
in relation to the need for energy. Only a weak signal
will be sent to the centres in the medulla oblongata to
the heart and lungs. If in a paraganglion cell a low
concentration of SDH protein is present, this cell will tend
to divide. SDH proteins take care of differentiation and
stabilization, and inhibit cell division. For that reason SDH
genes are called tumour-suppressor genes. An overview
of the PGL genes is given in Table 1.
T Th he e P PG GL L g ge en ne es s a an nd d c co om mp pl le ex x I II I 
1 1.. S SD DH HD D g ge en ne e 1 1 ( (P PG GL L1 1) )
This is the most important paraganglioma gene. It
is located on the long arm of chromosome 11 (11q23)
[3]. The gene encodes an anchor protein, SDHD, that
belongs to the succinate dehydrogenase mitochondrial
complex II. This enzyme is involved in cell metabolism
and energy supply. Expression of this gene is subject
to genomic imprinting. 
2 2.. S SD DH HB B g ge en ne e ( (P PG GL L4 4) )
The SDHB gene is located on chromosome 1p35-p36.
It encodes the catalytic subunit B of the SDH complex.
The SDHB protein is involved in head and neck
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T Ta ab bl le e 1 1. . Overview of the PGL and SDH genes
P PG GL L g ge en ne e e en nc co od de ed d c ch hr ro om mo os so om ma al l  c ch ha ar ra ac ct te er ri is st ti ic cs s
P Pr ro ot te ei in n  l lo oc ca at ti io on n
PGL1 SDHD 11q23 maternal imprinting
PGL4 SDHB 1p35-36 autosomal dominant 
inheritance
PGL3 SDHC 1q21 autosomal dominant 
inheritance
PGL2 – 11q13 maternal imprinting*
SDHA 5p15 opticus atrophy, 
myopathy, ataxia, 
Leigh syndrome, 
recessive
no paragangliomas
* The PGL2 gene has not yet been identified. 
F Fi ig g. . 2 2. . Cells obtain their energy from their environment by oxidation of carbohydrates, proteins and triglycerides to CO2 and H2O. 
The energy from these macronutrients is transformed into ATP in 4 different stages 
Stage 1 – hydrolysis of macromolecules into monosaccharides, fatty acids, amino acids
Stage 2 – oxidation into Acetyl Co A
Stage 3 – Acetyl Co A oxidation into Tricarboxylic acid (TCA) cycle ﬁ CO2
Stage 4 – reduction NAD ﬁ NADH, FAD ﬁ FADH2, phosphorylation ATP ﬁ H2O and ATP
S St ta ag ge e 1 1
S St ta ag ge e 2 2
S St ta ag ge e 3 3
Proteins Carbohydrates Triglycerydes
Fatty acids Glucose Amino acids
H+ H+ H+ H+
H+
O2
2CO2
ADP ADP H2O NAD+ Succinate
Complex I Complex II Complex III Complex IV Complex V
Fumarate
Electrons
Pyruvate
Acetyl CoA
Tricarboxylic
acid cycle
Outer membrane
Matrix
Intermembrane
space
Inner membrane
mitochondrion
e- e- e-
CoQ
Cyt b
Cyt c
NADH
S St ta ag ge e 4 4
A
B
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paragangliomas and in paragangliomas of the adrenal
medulla [4]. In contrast to the SDHD gene, no imprinting
is present. Mutations in the SDHB gene give a higher
risk for malignant, especially extra-adrenal abdominal,
paragangliomas than SDHD mutations do [5-7].
3 3.. S SD DH HC C g ge en ne e ( (P PG GL L3 3) )
This gene is located on chromosome 1q21 and
encodes the second anchor protein (C) of the mito-
chondrial complex II. Also mutations in this gene may
cause hereditary paragangliomas; however, these
mutations occur less frequently than SDHD mutations [8].
4 4.. S SD DH HA A g ge en ne e ( (t th hi is s i is s n no ot t a a P PG GL L g ge en ne e) )
This gene encodes the catalytic subunit A of
mitochondrial complex II. Mutations in this gene cause
a disease involving a combination of atrophy of the
optical nerve, myopathy and ataxia, although without
paragangliomas. This syndrome is called Leigh’s
syndrome. The gene is located on chromosome 5p15.
T Th he e P PG GL L2 2 g ge en ne e 
The PGL2 gene has not yet been identified. This
putative gene is located on chromosome 11 in the
region of 11q13 [9]. In this region no other genes
involved in the SDH mitochondrial complex II are found. 
T Tr ra an ns sm mi is ss si io on n o of f t th he e d di is se ea as se e
SDHB and SDHC families show autosomal
dominant inheritance of the disease, whereas SDHD
and PGL2 families only have an autosomal dominant
pattern of inheritance if the disease gene is transmitted
by the father (see paragraph below).
I In nh he er ri it ta an nc ce e o of f t th he e e ex xp pr re es ss si io on n 
o of f p pa ar ra ag ga an ng gl li io om ma as s. . T Th he e c co on nc ce ep pt t 
o of f g ge en no om mi ic c i im mp pr ri in nt ti in ng g
If a child inherits a mutated paraganglioma gene
from one of its parents, it becomes a disease-gene
male and female without genetic predisposition
male and female disease gene carrier without expression (imprinting)
male and female disease gene carrier with expression of the disease 
1
1
1
12 345 67 89
2 3 45 6 8 7
2
I
II
III
IV
3 4
2
F Fi ig g. . 3 3. . Imaginary example of a family with hereditary paragangliomas and genomic imprinting
The pedigree has four generations (I-IV). Expression of the disease skips one or two generations. In these generations, the genetic predisposition is present.
In the first generation (I) the mother (I 2) is a carrier of the paraganglioma disease gene and has expression of the disease. Her daughter (II 1) inherited the
mutated paraganglioma gene, but will not develop paragangliomas. She will transfer the mutated paraganglioma gene to two of her children (daughter III 2
and son III 4). These children will not develop the disease, but pass the predisposition to the next generation. The granddaughter of (II 1) IV 1 has the predisposition
but no expression, whereas the grandson IV 3 and granddaughter IV 4 have both the predisposition and expression of the disease. 
The son (II 4) of I 2 has also inherited the disease gene from his mother, but will not have symptoms. His son (III 5) is a paraganglioma carrier and will have
complaints just the same as his sister III 7. His children (IV 6 and 7) have predisposition for paragangliomas and will have the disease. The son and daughter
(IV 8 and 9) of III 7 do inherit the mutated paraganglioma gene from their mother, but will not have symptoms.H He er re ed diit ta ar ry y C Ca an nc ce er r iin n C Clliin niic ca all P Pr ra ac ct tiic ce e 2006; 4(4) 174
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T Ta ab bl le e 2 2. . Guidelines for periodical examination
W Wh hi ic ch h d di is se ea as se e g ge en ne e c ca ar rr ri ie er r h ha as s t to o b be e i in nv ve es st ti ig ga at te ed d p pe er ri io od di ic ca al ll ly y a an nd d w wh he en n? ?
• Carriers of a hereditary mutation of the PGL1 or PGL2 gene only if they have inherited the disease gene from their father 
(the paternal PGL disease gene) (thus in SDHD and PGL-2)
• all carriers of a PGL 3 or PGL 4 disease gene, irrespective of the gender of the genetically affected parent
Preferably, DNA analysis should be performed at an age between 5 and 10 years. This is the age at which periodical screening should 
have been started. 
H Ho ow w f fr re eq qu ue en nt tl ly y d do oe es s p pe er ri io od di ic ca al l e ex xa am mi in na at ti io on n h ha av ve e t to o b be e p pe er rf fo or rm me ed d? ?
In cases where tumours grow slowly and there are no symptoms or signs of expression of the disease, every three years:
• 24-hour urine on metabolites of noradrenaline and adrenaline
• ultrasound of the neck
• duplex examination of blood vessels in the neck
• MRI from the age of 10 onwards
If there are symptoms or signs of expression of the disease:
Consider surgical removal and in any case every year:
• 24-hour urine on metabolites of noradrenaline and adrenaline
• ultrasound of the neck
• duplex examination of blood vessels in the neck
• MRI from the age of 10 onwards
carrier. Yet it does not always have to experience
complaints in the course of its life. Whether the child
will have expression of the disease depends on the
gender of the parent that passed on the genetic
predisposition. If a father has the hereditary
predisposition, half of his children irrespectively of sex
will have both predisposition and expression of the
disease. If the mother has the predisposition to the
disease, this predisposition is transmitted, but
expression does not occur. This phenomenon is called
“Maternal imprinting”: the gene that causes the
disease is switched off (suppressed) if it is transmitted
via the egg cell. In contrast, the same gene is fully
active if it is transmitted via the spermatozoon. In
“paternal imprinting” exactly the opposite occurs (e.g.
in pseudohypoparathyroidism).
Exclusive transmission of the disease via the father
may be explained by a hereditary mutation of the
SDHD gene from the father combined with imprinting
of the homologous allele from the mother, together
with the loss of 11p15, 5. This may occur by loss of
the whole maternal chromosome 11 [10].
P Pe er ri io od di ic ca al l e ex xa am mi in na at ti io on n
Treatment of small tumours involves less risk than
larger ones. For that reason, periodical examination and
early treatment are recommended. Knowledge about the
mutation and expression of the disease within the family
is desired. The protocol for periodic clinical examination
depends on these data. The guidelines for examination,
the individuals to be examined, and the frequency and
methods of investigation are given in Table 2. In all
carriers of a mutation life-long follow-up is indicated. 
D DN NA A d di ia ag gn no os si is s
In children from well-known families identified with
paragangliomas, DNA analysis should be performed
preferably at an age between 5 and 10 years. This is
the age at which periodical examination should be
started [11].
If in patients with apparently sporadic tumours the
family history raises suspicion about the occurrence of
paraganglioma-associated tumours, DNA analysis is
indicated. If a phaeochromocytoma or paraganglioma
is revealed at a young age or if multiple or bilateral
tumours are encountered whereas the family history is
negative, DNA analysis may be performed [12-14].
V Vi is su ua al li is sa at ti io on n o of f t tu um mo ou ur rs s
R Ra ad di io ol lo og gi ic ca al l e ex xa am mi in na at ti io on n
Routinely periodical examination using ionising
radiation has to be avoided. 
Ultrasound-Doppler or duplex examination may
clarify how blood supply and the direction of growth
of a paraganglioma occur, and thus whether a
paraganglioma finds its origin in the glomus caroticum,
the nervus vagus or in the ganglion jugulotympanicum. 
MR angiography enables mapping of blood supply.
Digital subtraction angiography may reveal particular
details.H He er re ed diit ta ar ry y C Ca an nc ce er r iin n C Clliin niic ca all P Pr ra ac ct tiic ce e 2006; 4(4) 175
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N Nu uc cl le ea ar r e ex xa am mi in na at ti io on n 
Metaiodobenzylguanidine (MIBG) and somatostatin-
receptor scintigraphy enable the localization of additional
lesions or metastases. If positive, there may be conse-
quences for treatment. Overproduction of noradrenalin
occurs in 37.5% and phaeochromocytomas occur in 20%
[15]. Overproduction of serotonin occurs in only 3%;
however, the precursor 5-hydroxytryptophane (5 (OH)
HTP) is over-produced much more frequently.
Paragangliomas take up precursors of biogenic
amines and this capacity enables localisation of small
paragangliomas. Positron emission tomography (PET)
using 
11C-5-hydroxytryptophane (5HTP)-PET and/or 
6-[
18F]-fluorodopamine-PET may be applied [16, 17].
S Su ur rg gi ic ca al l t tr re ea at tm me en nt t
Early detection and treatment of tumours result in the
smallest risk for morbidity from surgery. In larger
paragangliomas, embolization of the main arterial blood
supply preoperatively may reduce the risk of haemorrhage
or other complications during surgery. This procedure
belongs in experienced hands, because in e.g. glomus
caroticum tumours there is a considerable risk of an
embolism to the brain. Preferably, suspected lymph nodes
on the side of the paraganglioma have to be removed
during surgery, even if the risk is small that metastases
are present [18-20]. In the case of large tumours, it will
be impossible to treat curatively. Conservative surgical
treatment may leave the large vessels intact so that
morbidity is limited. Preferably, surgery is performed by 
a team with knowledge and experience in the head and
neck region (throat, nose, and ear physician, head and
neck surgeon, and a vascular surgeon) experienced with
vascular reconstruction. 
Many paragangliomas are able to produce
catecholamines, especially dopamine and noradrenaline,
and if localised in the adrenal glands also adrenaline.
Preoperative treatment with alpha- and beta-receptor
blocking agents may be useful. 
I If f s su ur rg gi ic ca al l t tr re ea at tm me en nt t 
i is s n no ot t p po os ss si ib bl le e a an ny ym mo or re e
If intracranial extension is present and removal of the
paraganglioma is not possible without serious deletion
of surrounding structures (nerves and blood vessels) or if
metastases are present at a distance, treatment with other
methods may be discussed. Treatment with somatostatin
analogues appears to have little effect on the diameter
of a paraganglioma, but may give subjective improve-
ment of symptoms in malignant paragangliomas. 
Therapy with radioactive octreotide or MIBG may be
effective. Also, in a selected group of patients, a favo-
urable result may be expected from external beam
radiation. Stereotactic radiosurgery (gamma knife surgery)
may provide relief of symptoms. In the case of malignant
paragangliomas, one may expect partial remission from
chemotherapy with cyclophosphamide, vincristine,
dacarbazine (CVD), with or without doxorubicin [21, 22].
P Pr ra ac ct ti ic ca al l g gu ui id de el li in ne es s f fo or r c cl li in ni ic ci ia an ns s
• • e es sp pe ec ci ia al ll ly y c ch hi il ld dr re en n o of f f fa at th he er rs s w wi it th h a a S SD DH HD D
m mu ut ta at ti io on n h ha av ve e t to o b be e i in nv ve es st ti ig ga at te ed d p pe er ri io od di ic ca al ll ly y 
• • e ea ar rl ly y d di ia ag gn no os si is s i is s i in nd di ic ca at te ed d, , b be ec ca au us se e m mo or rb bi id di it ty y
i is s r re el la at te ed d t to o t th he e d di ia am me et te er r o of f t th he e t tu um mo ou ur r
• • i if f p po os ss si ib bl le e, , r re es se ec ct ti io on n o of f a a p pa ar ra ag ga an ng gl li io om ma a h ha as s
t to o b be e p pe er rf fo or rm me ed d a at t a an n e ea ar rl ly y s st ta ag ge e 
• • p pr re ef fe er ra ab bl ly y, , t th he e s su ur rg gi ic ca al l p pr ro oc ce ed du ur re e s sh ho ou ul ld d b be e
p pe er rf fo or rm me ed d b by y s su ur rg ge eo on ns s w wi it th h e ex xp pe er ri ie en nc ce e i in n t th he e
h he ea ad d a an nd d n ne ec ck k r re eg gi io on n a an nd d i in n t te ec ch hn ni iq qu ue es s o of f
v va as sc cu ul la ar r r re ec co on ns st tr ru uc ct ti io on n 
• • D DN NA A a an na al ly ys si is s o of f c ch hi il ld dr re en n f fr ro om m f fa am mi il li ie es s w wi it th h 
a a k kn no ow wn n S SD DH H m mu ut ta at ti io on n h ha as s t to o b be e p pe er rf fo or rm me ed d
b be ef fo or re e t th he e a ag ge e o of f 5 5 y ye ea ar rs s
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